Mannkind

Welcome To The Mannkind HUB On AGORACOM Edit this title from the Fast Facts Section
"AfrezzaUser" Returns
about 11 years ago
0
0
0
0
0
0
0
2

The guy doing most of the technical talking is Bob. I have not heard him before but he appeared to have a handle on the data.

I find it interesting that this was a topline data analysis yet most of the questions were from the assistants of the assigned analysts. The only name I recognized was Simon from Cowen.

The goal of non-inferiority was met in both trials. Without a major in depth analysis of the data how does one separate the impact of Afrezza from the other drugs taken in the studies?

I think we should let them absorb the studies and then decide whether or not the drug will perform as expected.

Swing

Please login to post a reply
swingtrader88
City
Coppell, Texas
Rank
Vice President
Activity Points
1424
Rating
Your Rating
Date Joined
03/20/2012
Social Links
Private Message
Mannkind
Symbol
MNKD
Exchange
NAZ
Shares
Industry
Technology & Medical
Website
Create a Post